Cargando…

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bray, Steven M., Lee, Jeeyun, Kim, Seung Tae, Hur, Joon Young, Ebert, Philip J., Calley, John N., Wulur, Isabella H., Gopalappa, Thejaswini, Wong, Swee Seong, Qian, Hui-Rong, Ting, Jason C., Liu, Jiangang, Willard, Melinda D., Novosiadly, Ruslan D., Park, Young Suk, Park, Joon Oh, Lim, Ho Yeong, Kang, Won Ki, Aggarwal, Amit, Kim, Hee Cheol, Reinhard, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814827/ https://www.ncbi.nlm.nih.gov/pubmed/31653970 http://dx.doi.org/10.1038/s41598-019-51981-5

Ejemplares similares

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2017)

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
por: Kim, Ju Sun, et al.
Publicado: (2017)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line
por: Kim, Seung Tae, et al.
Publicado: (2018)

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

High-content molecular profiling of T-cell therapy in oncology
por: Novosiadly, Ruslan, et al.
Publicado: (2016)

Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma
por: Peille, Anne-Lise, et al.
Publicado: (2020)

Author Correction: Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma
por: Peille, Anne-Lise, et al.
Publicado: (2020)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
por: Cho, Jang Ho, et al.
Publicado: (2019)

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
por: Lee, Taehyang, et al.
Publicado: (2018)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis
por: Liu, Jiangang, et al.
Publicado: (2020)

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
por: Jung, Ki Sun, et al.
Publicado: (2017)

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
por: Kim, Seung Tae, et al.
Publicado: (2016)

Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma
por: Park, Joon Suk, et al.
Publicado: (2013)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
por: Lee, Su Jin, et al.
Publicado: (2018)

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs
por: Kim, Hee Kyung, et al.
Publicado: (2017)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients
por: Park, Jin Hyun, et al.
Publicado: (2022)

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
por: Lim, Sung Won, et al.
Publicado: (2018)

Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection
por: Park, Kyung Hee, et al.
Publicado: (2021)

Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2015)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Anti-VEGF-refractory Exudative Age-related Macular Degeneration: Differential Response According to Features on Optical Coherence Tomography
por: Shin, Joo Young, et al.
Publicado: (2013)

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Kim, Youjin, et al.
Publicado: (2019)

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
por: Yoon, Sang Eun, et al.
Publicado: (2019)

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Moonjin, et al.
Publicado: (2016)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
por: Kim, Seung Tae, et al.
Publicado: (2016)

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
por: Johnson, Radia M., et al.
Publicado: (2022)

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer
por: Ko, Jihoon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_co0mjgvsm9ckuf734vjlu2ejoa